Following the formation of a dedicated strategic business unit oncology earlier this year within its pharmaceuticals division, Bayer announced today to further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership.
This unit will combine all research and development activities for therapeutic areas cardiology, gynecology, ophthalmology, hematology as well as oncology research within the company’s pharmaceuticals division.
Joerg Moeller, 53, currently Head of Development at Bayer’s pharmaceuticals division will become Head of Research and Development effective January 1, 2018.
“The combined organization will enable us to seamlessly steer all the important activities of Research and Development, with a single objective to further enhance the delivery of much needed new treatment options to patients,” said Dieter Weinand, President of Bayer’s Pharmaceuticals Division and Member of the Board of Management of Bayer AG. “Joerg has an exceptional track record of bringing new medicines to patients, which have the potential to increase their quality of life and address serious medical conditions, and I trust that our team will be even more successful in doing so together under his leadership.”
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.